Classer les publications sur l'année
-
Ăconomie de la santĂ©
Multiple Source of Information to Characterize the Clinical, Therapeutic Management and Economic Burden of Patients with Multiple Sclerosis in France.
EPSTEIN J, DETOURNAY B , GUILLEMIN F, DEBOUVERIE M, COUSIN M, TEHARD B, GAROT T, BITOUN L, SOUDANT M , DEPOORTERE PH, PAU D
Value in Health ; 2017;20(9):a719
-
Santé publique
De lâintĂ©rĂȘt/de la possibilitĂ© dâutiliser les donnĂ©es de la base Sniiram pour identifier le parcours de soins des enfants dĂ©cĂ©dĂ©s de maladie en Ăle-de-France en 2012â2013.
DONIO V, AUVRIGNON A, PELLEGRINO B, COUROUVE L, NISENBAUM N, VIALLE G, GABOLDE M, DETOURNAY B
Revue D'ĂPIDEMIOLOGIE ET DE SANTE PUBLIQUE ; 2017;65(S3):S126
-
Ăconomie de la santĂ©
Le coût des hospitalisations pour hypoglycémie en France chez les patients diabétiques de type 2
DETOURNAY B, HALIMI S, LEVY P, BEC M, TORRETON E, DEJAGER S.
Revue d'ĂpidĂ©miologie et de SantĂ© Publique ; 2017;65(S3):S137-S138
-
Ăconomie de la santĂ©
Effect of Multiple Sclerosis on Work Productivity
DETOURNAY B, COUSIN M, GOURMELEN J, PAU D, PINGUET JM, TEHARD B, COZZONE D
Value in Health ; 2017;20(9):a725
-
Ăconomie de la santĂ©
Effect of Multiple Sclerosis on Work Productivity
DETOURNAY B, COUSIN M, GOURMELEN J, PAU D, PINGUET JM, TEHARD B, COZZONE D
Value in Health ; 2017;20(9):a725
-
Ăconomie de la santĂ©
The Direct Cost of Patients With Multiple Sclerosis In France
DETOURNAY B, COUSIN M, GOURMELEN J, L. BITOUN L, PAU D, COZZONE D, B. TEHARD B
Value in Health ; 2017;20(9):a721
-
Ăconomie de la santĂ©
The Direct Cost of Patients With Multiple Sclerosis In France
DETOURNAY B, COUSIN M, GOURMELEN J, L. BITOUN L, PAU D, COZZONE D, B. TEHARD B
Value in Health ; 2017;20(9):a721
-
Ăconomie de la santĂ©
What is the budget impact of a new treatment or new health technology arriving on the market?
DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; participants of round table No. 3 of Giens XXXIII
Therapie ; 2017;72(1):93-103
-
Ăconomie de la santĂ©
Quel impact budgĂ©taire pour lâarrivĂ©e dâun nouveau traitement ou dâune nouvelle technologie de santĂ©Â ?
DERVAUX B, LE FUR C, DUBOIS S, JOSSERAN A, DETOURNAY B; les participants Ă la table ronde n(o)Â 3 de Giens XXXIII.
Therapie ; 2017;72(1):81-91
-
Ăconomie de la santĂ©
Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France
FERNANDEZ H, JOURDAIN O, VILLEFRANQUE V, LEHMANN M, LAFUMA A, TRANCART M.
BMJ Open ; 2017;7(9):e015571
-
Ăconomie de la santĂ©
Burden of severe spondyloarthritis in France: A nationwide assessment of prevalence, associated comorbidities and cost.
CLAUDEPIERRE P, FAGNANI F, CUKIERMAN G, DE CHALUS T, JOUBERT JM, LAURENDEAU C, GOURMELEN J, BREBAN M
Joint Bone Spine ; 2019;86(1);69-75
-
Pharmaco-Epidémiologie
Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting.
BARBUT F, GALPERINE T, VANHEMS P, LE MONNIER A, DURAND-GASSELIN B, CANIS F, JEANBAT V, DUBURCQ A, ALAMI S, BENSOUSSAN C, FAGNANI F.
Health Qual Life Outcomes ; 2019;17(1);6
-
Ăconomie de la santĂ©
Economic burden of thromboembolic and hemorrhagic complications in non-valvular atrial fibrillation in Algeria (the ELRAGFA study)
BOUAME M, ALI LAHMAR M, BOUAFIA MT, HAMMOUDI N, CHENTIR MT, ATHMANE MA, KARA S, TRANCART M, YILDIZ L, CHEYNEL J, SOUALMI R.
J Med Econ ; 2018; 21(12):1213-1220
-
Biométrie et Analyses de bases de données/SNDS
Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.
AGOSTINI A, GODARD C, LAURENDEAU C, BENMAHMOUD ZOUBIR A, LAFUMA A, LĂVY-BACHELOT L, GOURMELEN J, LINET T.
Eur J Contracept Reprod Health Care ; 2018;23(6):421-426
-
Santé publique
Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France.
GOZLAN G, LECARDEUR L, MONFORT AS, DOZ M, ORTIZ I, LARROUMETS P, LAFUMA A.
Encephale ; 2018 ;44(6):496-503.
  Â